Archive: Company News
Company News: BellaSeno and Charité – Universitätsmedizin Berlin Collaborate Under BMBF-Funded SyMBoD Consortium
— Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes
— BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485
BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charité – Universitätsmedizin Berlin under the recently established SyMBoD consortium.
Company News: BellaSeno’s Senella® Medical Implant Technology Named a Bronze Winner of the 2020 Edison Awards
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Senella® implant technology has won a Bronze Edison Award 2020 in the category Medical / Dental, subcategory Medical Implants.
Company News: Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe
– Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours
– Test kit to be made available via Curetis’ European sales channels
– Synergies with Curetis Unyvero HPN panel for pneumonia testing for bacterial co-infections in Covid-19 patients
Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it starts offering a CE-IVD certified real-time PCR test kit for SARS-CoV2 (also known as 2019-nCov), the causal pathogen of Corona Virus Disease 2019 (Covid-19).
Company News: Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key Financials and Provides Business Update
— Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018
— More than tripled total contract order volume received year-over-year to about EUR 3.4 million 2019
— Curetis N.V. shareholders to vote on March 10, 2020 on planned business combination with OpGen, Inc.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced preliminary. unaudited condensed combined key financials for the fiscal year 2019 and provided a business update for 2020 year-to-date.